Trial Profile
Phase II trial of coltuximab ravtansine in combination with anticancer agents in patients with B-cell malignancies
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 04 May 2016
Price :
$35
*
At a glance
- Drugs Coltuximab ravtansine (Primary) ; Antineoplastics
- Indications B-cell lymphoma
- Focus Therapeutic Use
- 29 Apr 2016 According to an ImmunoGen media release, this trial is expected to initiate in first half of 2017.
- 10 Jan 2016 According to an ImmunoGen media release, company is planning to initiate this trial in the mid year of 2016.
- 05 Aug 2015 New trial record